arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Niagen Bioscience, Inc.

NAGE
$3.01 ▼ -0.09 (-2.90%) at close
Materials ·Medicinal Chemicals & Botanical Products ·USMedicinal Chemicals & Botanical Products
67 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
80
Health
Good
Bullish
auto_awesome

Analytical Summary

Niagen Bioscience, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $238.8M
Dividend Yield
Revenue Growth -4.3%
Op. Margin 2.4%
ROIC 0.8%
FCF / Share $0.03
Trailing P/E 301.0x
Price / Book 2.9x
FCF Yield 1.2%
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$29.79M
↓ -4.3%
Net Income Profit after all expenses
$963.00K
↓ -73.3%
Operating Margin Operating profit as % of sales
2.4%
↓ -53.1% 62th
FCF / Share Free cash flow per share
$0.03
↑ +333.9%
Long-Term Debt Long-term obligations
$0.00
↓ -100.0%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
65
Returns
89
Financial Health
100
Cash Quality
52

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 17 years · 67 quarters